Indivior (INDV.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec17

Indivior plc Publishes Research: 300mg SUBLOCADE® More Effective for Frequent Fentanyl Users

16:30

Nov20

Indivior plc pays $295 million to settle legacy obligations with the US Department of Justice

21:01

Nov3

Indivior presents new evidence on SUBLOCADE's impact on opioid use disorder

13:03

Oct30

Indivior released FY2025 9 Months Earnings on October 30 Pre-Market EST, actual revenue USD 882 M, actual EPS USD 0.849

13:30

Indivior released FY2025 Q3 earnings on October 30 Pre-Market (EST), actual revenue USD 314 M (forecast USD 261.92 M), actual EPS USD 0.33 (forecast USD 0.23)

13:30

Indivior Reports Q3 Net Revenue Growth of 2% and Raises Full-Year Guidance

11:39

Schedules & Filings

Schedules

Filings

Oct30

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 314 M, Net Income 42 M, EPS 0.33

Jul31

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 302 M, Net Income 18 M, EPS 0.14

Apr24

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 266 M, Net Income 47 M, EPS 0.379

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change